en · de · es · fr · pt
sr9009-notes.peptides7250.com › Wiki › Background And Mechanism Of Sr9009 — Complete Guide

Background And Mechanism Of Sr9009 — Complete Guide

By Editorial Desk · published 2025-09-26 · last reviewed 2025-11-01 · Wiki

A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Related pages on this site

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Supporting material

=== Treatment by medical professionals === In a healthcare setting, treatment depends on the severity of symptoms and intravenous access. If a patient is conscious and able to swallow safely, food or drink may be administered, as well as glucose tabs or gel. In those with intravenous access, 25 grams of 50% dextrose is commonly administered. When there is no intravenous access, intramuscular or intra-nasal glucagon may be administered.

=== Invention of products === In the 18th century, the potato was actively studied in all its practical aspects: cultivation and reproduction, diseases, use as a food for animals and as a vegetable for humans. Its use was also considered in the same way as that of cereals which produce flour – and therefore bread – but also alcohol. Other uses and by-products were born, some of which still exist in the 21st century.

=== Recombinant antibodies === Recombinant antibodies (rAbs) are produced in vitro by the means of expression systems based on mammalian cells. Their monospecific binding to a specific epitope makes rAbs eligible not only for research purposes, but also as therapy options against certain cancer types, infections and autoimmune diseases.

Actinidia chinensis var. deliciosa (kiwifruit) Ambrosia artemisiifolia (short ragweed) Ananas comosus (pineapple) Apium graveolens (celery) Arachis hypogaea (peanut) Artemisia vulgaris (mugwort) Betula verrucosa (European white birch) and Betula pendula (silver birch) Capsicum annuum (bell pepper) Chenopodium album (pigweed) Citrus sinensis (sweet orange) Corylus avellana (hazel) Cucumis melo (muskmelon) Daucus carota (carrot) Glycine max (soybean) Helianthus annuus (sunflower) Hevea brasiliensis (para rubber tree [latex]) Malus domestica (apple) Olea europaea (olive) Phleum pratense (timothy grass) Phoenix dactylifera (date palm) Prunus persica (peach) Pyrus communis (pear) Salsola kali (Russian thistle) Sinapis alba (yellow mustard) Solanum lycopersicum (tomato)

Sources: en.wikipedia.org

Notes from published material

=== Spukie === The term spukie ("spukkie" or "spuckie") is unique to the city of Boston and derives from the Italian word spuccadella, meaning "long roll". The word spuccadella is not typically found in Italian dictionaries, which may suggest that it could be a regional Italian dialect, or possibly a Boston Italian-American innovation. Spukie is typically heard in parts of Dorchester and South Boston. Some bakeries in Boston's North End neighborhood have homemade spuccadellas for sale.

== Techniques == Vacuum pumps are combined with chambers and operational procedures into a wide variety of vacuum systems. Sometimes more than one pump will be used (in series or in parallel) in a single application. A partial vacuum, or rough vacuum, can be created using a positive displacement pump that transports a gas load from an inlet port to an outlet (exhaust) port. Because of their mechanical limitations, such pumps can only achieve a low vacuum. To achieve a higher vacuum, other techniques must then be used, typically in series (usually following an initial fast pump down with a positive displacement pump). Some examples might be use of an oil sealed rotary vane pump (the most common positive displacement pump) backing a diffusion pump, or a dry scroll pump backing a turbomolecular pump. There are other combinations depending on the level of vacuum being sought. Achieving high vacuum is difficult because all of the materials exposed to the vacuum must be carefully evaluated for their outgassing and vapor pressure properties. For example, oils, greases, and rubber or plastic gaskets used as seals for the vacuum chamber must not boil off when exposed to the vacuum, or the gases they produce would prevent the creation of the desired degree of vacuum. Often, all of the surfaces exposed to the vacuum must be baked at high temperature to drive off adsorbed gases. Outgassing can also be reduced simply by desiccation prior to vacuum pumping.

===== MeSH D08.811.682.830 – succinate cytochrome c oxidoreductase ===== MeSH D08.811.682.830.249 – electron transport complex ii MeSH D08.811.682.830.249.500 – succinate dehydrogenase MeSH D08.811.682.830.500 – electron transport complex iii

=== Denise Oldroyd === Denise Oldroyd (Fiona Button) is Yasmin's lawyer, and sister of her ex-boyfriend Seb. Denise represents Yasmin following the publication of her father's historic embezzlement from the family publishing company. She also has a brief affair with Eric that begins after he joins her and Yasmin on a cocaine bender. When Hanani Publishing decides to pay off Charles' various legal settlements in exchange for making Yasmin the face of the scandal, Denise encourages Yasmin to go along with the deal to protect the victims of Charles' sexual abuse, but Yasmin decides to fight her father's company in court.

Shawn voiced his support for the Palestinian people during the 2014 Gaza War. He has been on the advisory board of Jewish Voice for Peace. On October 16, 2023, Shawn spoke at a Washington, D.C., rally organized by Jewish Voice for Peace and IfNotNow. The rally called for a ceasefire in the Gaza war and for President Joe Biden to support a ceasefire. Also that month, Shawn was among the artists to sign the Artists4Ceasefire campaign's open letter urging Biden to push for a ceasefire. In April 2024, Shawn narrated a political ad by a group of organizations opposing the American Israel Public Affairs Committee's influence in Democratic Party primaries. In a January 2025 interview, Shawn compared Israel to Nazi Germany, saying the Israelis were "doing evil that is just as great as what the Nazis did. And in some ways, it's worse, because they kind of boast about it. Hitler had the decency to try to keep it secret... the Israelis are almost proud of it, and it's demonically evil."

Sources: en.wikipedia.org

Further detail

NASA orders four astronauts of the Crew-12 mission to prepare to evacuate the International Space Station due to an air leak on Russia's Zvezda service module. The order is rescinded two hours later as the air leaks are sealed. Energy Secretary Chris Wright announces a nuclear microreactor developed by Antares Nuclear at the Idaho National Laboratory reached criticality, a milestone for the Trump administration's development of nuclear energy. NBC News reports that the Pentagon raised the threat of Israeli spying on the U.S. to the highest level; Israeli and American officials deny the veracity of the report. June 6 – Iran war: The United States military strikes Iranian coastal radar sites after shooting down Iranian drones launched towards the Strait of Hormuz. Iran responds by launching missiles and drones towards U.S. military facilities in Bahrain and Kuwait. June 7 – In an interview with NBC News' Meet the Press, Trump repeats unsubstantiated claims that the 2020 United States presidential election and ongoing California primary elections were "rigged", and declines to rule out compensation for some people prosecuted over the January 6 United States Capitol attack. Trump walks out after journalist Kristen Welker presses him to provide evidence of his claims. June 8 Federal judge Leo Sorokin voids President Trump's $100,000 fee requirement for H-1B visa applications, ruling that Trump lacked congressional authority to impose what amounted to a tax on the programme. The Kennedy Center removes Donald Trump's name from the building following the ruling. A U.S.

Reprocessed uranium is also mainly 238U, with about as much uranium-235 as natural uranium, a comparable proportion of uranium-236, and much smaller amounts of other isotopes of uranium such as uranium-234, uranium-233, and uranium-232.

=== Final tour and death in New York === Thomas left Laugharne on 9 October 1953 on the first leg of his fourth trip to America. He called on his mother, Florence, to say goodbye: "He always felt that he had to get out from this country because of his chest being so bad." Thomas had suffered from chest problems for most of his life, though they began in earnest soon after he moved in May 1949 to the Boat House at Laugharne—the "bronchial heronry", as he called it. Within weeks of moving in, he visited a local doctor, who prescribed medicine for both his chest and throat. While waiting in London before his flight, Thomas stayed with the comedian Harry Locke and worked on Under Milk Wood. Locke noted that Thomas was having trouble with his chest, "terrible" coughing fits that made him go purple in the face. He was also using an inhaler to help his breathing. There were reports, too, that Thomas was also having blackouts. His visit to the BBC producer Philip Burton, a few days before he left for New York, was interrupted by a blackout. On his last night in London, he had another in the company of his fellow poet Louis MacNeice. Thomas arrived in New York on 20 October 1953 to undertake further performances of Under Milk Wood, organised by John Brinnin, his American agent and Director of the Poetry Centre. Brinnin did not travel to New York but remained in Boston to write. He handed responsibility to his assistant, Liz Reitell. She met Thomas at Idlewild Airport and was shocked at his appearance.

=== Antibiotic-associated diarrhea === Evidence supports the use of S. boulardii for the prevention of antibiotic-associated diarrhea (AAD) in both adults and children. The efficacy of probiotics in preventing AAD appears to depend on the specific strain used and the administered dose. A 2015 meta-analysis of 21 randomized controlled trials involving 4,780 participants found that S. boulardii significantly reduced the risk of AAD in adults and children. High-dose probiotics, including S. boulardii and Lactobacillus rhamnosus (more than 5 billion colony-forming units per day), were reported to be moderately effective in preventing AAD in children and may also reduce the duration of diarrhea, without serious adverse effects.

=== Clinical quantification and genotyping === Viruses can be present in humans due to direct infection or co-infections which makes diagnosis difficult using classical techniques and can result in an incorrect prognosis and treatment. The use of qPCR allows both the quantification and genotyping (characterization of the strain, carried out using melting curves) of a virus such as the hepatitis B virus. The degree of infection, quantified as the copies of the viral genome per unit of the patient's tissue, is relevant in many cases; for example, the probability that the type 1 herpes simplex virus reactivates is related to the number of infected neurons in the ganglia. This quantification is carried out either with reverse transcription or without it, as occurs if the virus becomes integrated in the human genome at any point in its cycle, such as happens in the case of HPV (human papillomavirus), where some of its variants are associated with the appearance of cervical cancer. Real-time PCR has also brought the quantization of human cytomegalovirus (CMV) which is seen in patients who are immunosuppressed following solid organ or bone marrow transplantation.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

Network